Genetic Tests for Common Diseases: Understanding Risk and Empowering Prevention-Daniel Siu-01/11/2011 - 6:00pm

Event Information
Event Topic: 
Genetic Tests for Common Diseases: Understanding Risk and Empowering Prevention
Event Date: 
01/11/2011 - 6:00pm
Event Location: 
WSG&R Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306
Speaker Information
Event Speaker: 
Daniel Siu
Event Speaker Title: 
Sr. Director Business Development US & Canada, & Managing Director Asia Pacific
Event Speaker Company: 
deCODE Genetics
Event Speaker Bio: 

Daniel Siu is the Managing Director at deCODE Genetics responsible for the company's genetic risk assessment business. He manages sales and partnership deals in the US, Canada and Asia Pacific. Previously, he held product management positions at both start-up and well-established companies including Ingenuity Systems, Aclara Biosciences, Dionex, Beckman Instruments and Applied BioSystems. Daniel has a BS degree in molecular biology from the University of Texas at Austin, MS degree in bioinorganic chemistry from the University of Minnesota, and an MBA degree from San Francisco State University. Daniel has over 20 years of experience in the genetic analysis business and has published two peer-reviewed journal articles.

Event Details
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

The presentation will focus on the recent commercialization of genetic risk assessment tests in the US and in Asia Pacific regions.

Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using the extensive Icelandic genealogy and large scale genotyping resources, deCODE has discovered key genetic risk factors for dozens of common complex diseases ranging from heart attack to prostate and breast cancers. deCODE successfully commercialized six DNA-based tests with a strong emphasize on applying clinical utilities to empower preventions. The deCODE Prostate Cancer test will be used as an example to highlight the integration of genetic risk assessment with standard medical practice. If time permits, the presenter will provide a snapshot of the large scale sequencing project underway in Iceland, from which even stronger genetic variants are expected to be discovered, resulted in development of more powerful risk assessment tools.